Jonathan Athayde1, Sarah C Davies1, Claire E Parker2, Leonardo Guizzetti2, Christopher Ma2,3, Reena Khanna1,2, Brian G Feagan1,2,4, Vipul Jairath5,6,7. 1. Department of Medicine, University of Western Ontario, London, ON, Canada. 2. Robarts Clinical Trials Inc., 100 Dundas St. #200, London, ON, N6A 5B6, Canada. 3. Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada. 4. Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, N6A 5B6, Canada. 5. Robarts Clinical Trials Inc., 100 Dundas St. #200, London, ON, N6A 5B6, Canada. vjairath@uwo.ca. 6. Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, N6A 5B6, Canada. vjairath@uwo.ca. 7. Division of Gastroenterology, Departments of Medicine, University of Western Ontario, London, ON, N6A 5B6, Canada. vjairath@uwo.ca.
Abstract
BACKGROUND: Approximately half of the patients with ulcerative colitis (UC) who undergo restorative proctocolectomy develop pouchitis within 10 years of surgery. Currently, there are no approved pouchitis treatments. It is important to quantify, and ultimately minimize, placebo rates to design and conduct efficient pouchitis trials. AIMS: To quantify the placebo rate observed in pouchitis randomized controlled trials (RCTs) in meta-analysis. METHODS: Embase, MEDLINE, and the Cochrane Library were searched from inception to November 3, 2017, for placebo-controlled RCTs enrolling adult UC patients with, or at risk for developing, pouchitis. A fixed-effect binomial-normal model was used to pool placebo rates on the log-odds (logit) scale. Proportions and 95% confidence intervals were reported. Outcomes of interest included development of pouchitis, induction of remission/response, and maintenance of remission/response. The Cochrane risk of bias tool was used to evaluate study quality. RESULTS: Twelve trials (five prevention, five induction, and two maintenance) enrolling a total of 229 placebo patients were eligible for inclusion. The pooled placebo rates for development of pouchitis and induction of response were 47% (95% CI 39-56%) and 24% (95% CI 14-37%), respectively. An insufficient number of trials prevented additional data pooling and meta-regression analysis and no consistent definitions of outcome were identified. CONCLUSIONS: No consistent methods for measuring pouchitis disease activity or defining response and remission were identified, highlighting the need for standardized definitions of outcomes for use in pouchitis trials. Additional high-quality trials are required to evaluate existing and novel therapies in this area.
BACKGROUND: Approximately half of the patients with ulcerative colitis (UC) who undergo restorative proctocolectomy develop pouchitis within 10 years of surgery. Currently, there are no approved pouchitis treatments. It is important to quantify, and ultimately minimize, placebo rates to design and conduct efficient pouchitis trials. AIMS: To quantify the placebo rate observed in pouchitis randomized controlled trials (RCTs) in meta-analysis. METHODS: Embase, MEDLINE, and the Cochrane Library were searched from inception to November 3, 2017, for placebo-controlled RCTs enrolling adult UC patients with, or at risk for developing, pouchitis. A fixed-effect binomial-normal model was used to pool placebo rates on the log-odds (logit) scale. Proportions and 95% confidence intervals were reported. Outcomes of interest included development of pouchitis, induction of remission/response, and maintenance of remission/response. The Cochrane risk of bias tool was used to evaluate study quality. RESULTS: Twelve trials (five prevention, five induction, and two maintenance) enrolling a total of 229 placebo patients were eligible for inclusion. The pooled placebo rates for development of pouchitis and induction of response were 47% (95% CI 39-56%) and 24% (95% CI 14-37%), respectively. An insufficient number of trials prevented additional data pooling and meta-regression analysis and no consistent definitions of outcome were identified. CONCLUSIONS: No consistent methods for measuring pouchitis disease activity or defining response and remission were identified, highlighting the need for standardized definitions of outcomes for use in pouchitis trials. Additional high-quality trials are required to evaluate existing and novel therapies in this area.
Authors: P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri Journal: Gastroenterology Date: 2000-08 Impact factor: 22.682
Authors: Klaus Gottlieb; Simon Travis; Brian Feagan; Fez Hussain; William J Sandborn; Paul Rutgeerts Journal: Inflamm Bowel Dis Date: 2015-10 Impact factor: 5.325
Authors: Shanika de Silva; Christopher Ma; Marie-Claude Proulx; Marcelo Crespin; Belle S Kaplan; James Hubbard; Martin Prusinkiewicz; Andrew Fong; Remo Panaccione; Subrata Ghosh; Paul L Beck; Anthony Maclean; Donald Buie; Gilaad G Kaplan Journal: Clin Gastroenterol Hepatol Date: 2011-07-30 Impact factor: 11.382
Authors: Sunil Samuel; Steven B Ingle; Shamina Dhillon; Siddhant Yadav; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; William J Sandborn; Edward V Loftus Journal: Inflamm Bowel Dis Date: 2013-08 Impact factor: 5.325
Authors: Bo Shen; Jean-Paul Achkar; Jason T Connor; Adrian H Ormsby; Feza H Remzi; Charles L Bevins; Aaron Brzezinski; Marlene L Bambrick; Victor W Fazio; Bret A Lashner Journal: Dis Colon Rectum Date: 2003-06 Impact factor: 4.585
Authors: W J Tremaine; W J Sandborn; B G Wolff; H A Carpenter; A R Zinsmeister; P P Metzger Journal: Aliment Pharmacol Ther Date: 1997-12 Impact factor: 8.171